Sophie X. Deng, MD, PhD, FARVO, has stepped into the role as the new 2025-2026 Association for Research and Ophthalmology (ARVO) president. Deng has been part of ARVO for more than 20 years, is a ...

The pivotal phase 3 clinical trial is the first of 2 that will evaluate the use of DURAVYU for the treatment of wet age-related macular degeneration. EyePoint Pharmaceuticals recently announced the ...

Retina specialist Priya Vakharia, MD, reveals promising ANX007 trial results, showing potential to prevent vision loss in geographic atrophy. Priya Vakharia, MD, a retina specialist at Retina Vitreous ...

Sylentis recently announced topline results from the SYL1801_II phase 2a study investigating SYL1801 for the treatment of neovascular age-related macular degeneration (nAMD). 1 SYL1801 is an ...

Retina specialist Priya Vakharia, MD, reveals promising ANX007 trial results, showing potential to prevent vision loss in geographic atrophy.

Biotechnology company Lineage Cell Therapeutics recently announced it will be presenting data from its phase 1/2a clinical study (NCT02286089) at the upcoming Clinical Trials at the Summit (CTS) 2025 ...

Ashvattha Therapeutics recently announced positive interim phase 2 results for migaldendranib (MGB). 1 MGB is described as a novel subcutaneously administered nanomedicine for the treatment of retinal ...

Kriya Therapeutics recently announced preclinical data on its gene therapy candidate KRIYA-825, a one-time gene therapy delivered by suprachoroidal injection, for the treatment of geographic atrophy ...

Four-year study shows faricimab in treat-and-extend regimen maintains vision for diabetic macular edema patients with significantly fewer injections over time. Matt Star, MD, assistant professor of ...

Ophthalmologist Tarek Hassan introduces new surgical approach for proliferative vitreoretinopathy, using precise small retinotomies instead of extensive retinal removal to improve patient outcomes.

Dilsher S. Dhoot, MD discusses how newer anti-VEGF treatments, particularly aflibercept 8mg, can provide improved anatomic outcomes and extended treatment intervals for patients with neovascular AMD ...